Two 59%+ winners, four above 25% in Aug – How this AI model keeps picking winners
Investing.com - JMP Securities has reiterated its Market Perform rating on Instil Bio Inc (NASDAQ:TIL) following the company’s second-quarter 2025 financial results and corporate milestone updates. The stock has shown remarkable momentum, delivering a 176% return over the past year, though InvestingPro data indicates high price volatility.
The research firm based its rating on a cash/share and platform value analysis, noting that Instil Bio recently announced potential data updates from its Chinese first-line non-small cell lung cancer (NSCLC) therapy combined with chemotherapy in the squamous cell population at the upcoming World Conference on Lung Cancer from September 6-9, 2025.
Instil Bio management confirmed plans to initiate a monotherapy U.S.-based dose escalation bridging study in relapsed/refractory solid tumors by year-end 2025, following FDA clearance of the company’s Investigational New Drug (IND) application.
JMP acknowledged that while the recently updated NSCLC data appears promising, and the reported $103.6 million cash on hand is sufficient to fund operations through key milestones, the firm believes shares are fairly valued at current levels. InvestingPro analysis supports this view, with a current Fair Value assessment suggesting the stock is fairly priced. The company maintains a healthy current ratio of 14.97, indicating strong short-term liquidity.
The research firm stated it will remain on the sidelines until it can evaluate a more robust set of clinical results from Instil Bio’s development programs. Analyst consensus remains cautiously optimistic, with price targets ranging from $51 to $180. Discover more valuable insights and 8 additional ProTips with InvestingPro.
In other recent news, Instil Bio Inc. announced the clearance of its Investigational New Drug (IND) application for AXN-2510 by the U.S. Food and Drug Administration. This clearance paves the way for a Phase 1 trial of AXN-2510, which is set to begin before the end of 2025, focusing on patients with relapsed or refractory solid tumors. The trial will assess the safety, efficacy, pharmacokinetics, and pharmacodynamics of the drug. In related developments, Instil Bio reported positive preliminary data from a Phase 2 study of its cancer therapy in China, showing promising response rates in patients with advanced non-small cell lung cancer.
Additionally, H.C. Wainwright reaffirmed its Buy rating on Instil Bio stock, influenced by recent strategic partnerships in the biopharmaceutical sector. Instil Bio has also appointed Dr. Jamie Freedman as its new Chief Medical Officer, bringing extensive experience in oncology drug development. Dr. Freedman’s role will be crucial in advancing the development of AXN-2510, a PD-L1xVEGF bispecific antibody. These developments highlight Instil Bio’s ongoing efforts to advance its therapeutic pipeline.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.